Abstract
Objectives: Older nursing home residents make up the population at greatest risk of morbidity and mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. No studies have examined the determinants of long-term antibody responses post vaccination in this group.
Design: Longitudinal cohort study.
Setting and participants: Residents from 5 nursing homes assessed before vaccination, and 5 weeks and 6 months post vaccination, with the BNT162b2 messenger RNA SARS-CoV-2 vaccine.
Methods: Comprehensive clinical assessment was performed, including assessment for comorbidity, frailty, and SARS-CoV-2 infection history. Serum nucleocapsid and anti-spike receptor binding domain (RBD) antibodies were analyzed at all timepoints. An in vitro angiotensin-converting enzyme (ACE2) receptor-spike RBD neutralization assay assessed serum neutralization capacity.
Results: Of 86 participants (81.1 ± 10.8 years; 65% female), just under half (45.4%; 39 of 86) had evidence of previous SARS-CoV-2 infection. All participants demonstrated a significant antibody response to vaccination at 5 weeks and a significant decline in this response by 6 months. SARS-CoV-2 infection history was the strongest predictor of antibody titer (log-transformed) at both 5 weeks [β: 3.00; 95% confidence interval (CI): 2.32-3.70; P < .001] and 6 months (β: 3.59; 95% CI: 2.89-4.28; P < .001). Independent of SARS-CoV-2 infection history, both age in years (β: -0.05; 95% CI: -0.08 to -0.02; P < .001) and frailty (β: -0.22; 95% CI: -0.33 to -0.11; P < .001) were associated with a significantly lower antibody titer at 6 months. Anti-spike antibody titers at both 5 weeks and 6 months significantly correlated with in vitro neutralization capacity.
Conclusions and implications: In older nursing home residents, SARS-CoV-2 infection history was the strongest predictor of anti-spike antibody titers at 6 months, whereas age and frailty were independently associated with lower titers at 6 months. Antibody titers significantly correlated with in vitro neutralization capacity. Although older SARS-CoV-2 naïve nursing home residents may be particularly vulnerable to breakthrough SARS-CoV-2 infection, the relationship between antibody titers, SARS-CoV-2 infection, and clinical outcomes remains to be fully elucidated in this vulnerable population.
Keywords: COVID-19; Nursing homes; SARS-CoV-2.0; antibody; long-term care; vaccine.
【저자키워드】 COVID-19, antibody, vaccine., Long-term care, nursing homes, SARS-CoV-2.0, 【초록키워드】 SARS-CoV-2, ACE2, Vaccine, coronavirus, vaccination, antibody, SARS-COV-2 infection, nursing home, Antibody Response, Infection, frailty, Comorbidity, risk, in vitro, severe acute respiratory syndrome Coronavirus, resident, SARS-CoV-2 vaccine, clinical outcomes, cohort study, Receptor binding domain, Clinical outcome, BNT162b2, Neutralization assay, nucleocapsid, RBD, morbidity, female, Antibody titer, Long-term care, Nursing, age, morbidity and mortality, receptor, determinants, respiratory, nursing homes, longitudinal, Antibody titers, Anti-spike, Serum Neutralization, anti-spike antibody, Angiotensin-converting enzyme, Evidence, angiotensin, neutralization capacity, evidence of, the strongest, independent of, vulnerable population, make up, determinant, Messenger RNA, acute respiratory syndrome, Older, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, 95% confidence interval, All participants, longitudinal cohort study, naïve, participant, timepoints, post vaccination, significantly lower, setting, Comprehensive, analyzed, examined, significantly, was performed, demonstrated, correlated, All participant, log-transformed, 【제목키워드】 SARS-CoV-2, resident, titer, Nursing, home,